Trazodone Discontinuation for Ineffective Insomnia Treatment
If trazodone is ineffective for insomnia, it should be tapered gradually rather than stopped abruptly, even though it lacks proven efficacy for this indication.
Rationale for Tapering
The FDA drug label explicitly warns about discontinuation syndrome with trazodone, stating that "adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures" 1. The label recommends "a gradual reduction in dosage rather than abrupt cessation is recommended whenever possible" 1.
This is further supported by clinical case reports demonstrating that withdrawal symptoms can develop despite gradual discontinuation, with the recommendation that "trazodone should be tapered off at a very slow rate" 2. The mechanism involves trazodone's effects on the serotonergic system, which may result in noradrenergic rebound after discontinuation, compounded by the short half-lives of trazodone and its active metabolite 2.
Evidence Against Trazodone Use for Insomnia
The 2020 VA/DoD guidelines explicitly advise against using trazodone for chronic insomnia disorder 3. A systematic review found no differences in sleep efficiency or discontinuation rates between trazodone (50-150 mg) and placebo, and while trazodone improved subjective sleep quality, there were no differences in sleep onset latency, total sleep time, or wake after sleep onset 3. The low-quality evidence supporting efficacy was outweighed by its adverse effect profile 3.
The 2017 American Academy of Sleep Medicine guideline similarly recommends against trazodone use for sleep onset or sleep maintenance insomnia 4.
Practical Tapering Approach
Recent evidence provides specific tapering guidance 5:
- After short-term use (1-2 weeks): Abrupt discontinuation may be acceptable
- After medium- or long-term use (>2 weeks): Gradual taper with 10-25% weekly dose reduction
- After high-dose (≥2/3 maximum dose) or long-term use (≥1 year): Consider a longer, slower taper
The 2008 AASM guidelines emphasize that "efforts should be made to employ the lowest effective maintenance dosage of medication and to taper medication when conditions allow" and that "medication tapering and discontinuation are facilitated by CBT-I" 6.
Alternative Treatment Strategy
When trazodone fails for insomnia:
- Initiate gradual taper (10-25% weekly dose reduction)
- Consider evidence-based alternatives: The recommended sequence for primary insomnia includes short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or ramelteon as first-line pharmacologic options 6
- Implement cognitive behavioral therapy for insomnia (CBT-I) concurrently, which facilitates medication discontinuation and provides durable benefit 6
Important Caveats
- Monitor for withdrawal symptoms during tapering, particularly insomnia rebound, which can be mistaken for treatment failure
- The FDA warns about cardiac arrhythmias, orthostatic hypotension, and QT prolongation with trazodone, making discontinuation particularly important in patients with cardiac risk factors 1
- Trazodone is not FDA-approved for insomnia, and its efficacy for this indication is not well established 6